Challenges in the transfer and scale-up of mini-tableting: Case study with losartan potassium.
Compaction simulator
Direct compression
Epidermolysis bullosa
Mini-tablets
Paediatric formulation
Rotary tablet press
Transfer and scale-up
Journal
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
07
06
2023
revised:
21
09
2023
accepted:
01
10
2023
medline:
6
11
2023
pubmed:
12
10
2023
entrez:
11
10
2023
Statut:
ppublish
Résumé
Mini-tablets (MTs) with losartan potassium were developed to treat the rare disease Epidermolysis Bullosa. The focus was placed on transfer and scale-up of a direct compressible formulation from the compaction simulator STYL'One Evo (CS) to the rotary tablet press Korsch XM 12 (RP). Transfer of tabletability and compactibility profiles from CS to RP did not show good agreement, e.g. at a tableting pressure of 125 MPa mean tensile strengths (TS) of 4 MPa on CS and 1-1.5 MPa on RP were reached. These results highlight the impact of the feed frame on final product qualities depending on process and material factors. In the scale-up studies the critical quality attributes (CQAs) mass variation, content uniformity, TS and disintegration time were investigated. After an appropriate run-up time, most CQAs reached a plateau, after reaching a balance between influx, efflux and distribution of lubricant in the feed frame. TS values of 1-2 MPa, disintegration times of max. 50 s, mass variation of 0.9-2.2 % (CV) and acceptance values below 15.0 were reached depending on chosen process parameters.
Identifiants
pubmed: 37820883
pii: S0939-6411(23)00261-8
doi: 10.1016/j.ejpb.2023.10.001
pii:
doi:
Substances chimiques
Losartan
JMS50MPO89
Tablets
0
Excipients
0
Powders
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-173Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.